Pancreatic Cancer Research

ResearcherMasaryk UniversityActive in the last 2 years

Igor Kišš

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7693-0659; OpenAlex author ID A5039214402. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 8

  1. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  2. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  3. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  4. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. Co-author DOI 10.3390/jcm9082440↗
  5. Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer. Last author DOI 10.2174/1389202921666191217095017↗
  6. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection Co-author PMID 31064193↗
  7. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical… Co-author DOI 10.21873/cgp.20090↗
  8. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13000-015-0272-6↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zev A. Wainberg · 3 shared papers, 2023–2025 · strength 0.54
  2. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  3. Eileen Mary O'Reilly · 3 shared papers, 2023–2025 · strength 0.54
  4. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  5. Christelle de la Fouchardière · 3 shared papers, 2023–2025 · strength 0.54
  6. Andrew Scott Paulson · 3 shared papers, 2023–2025 · strength 0.54
  7. Roberto Pazo-Cid · 3 shared papers, 2023–2025 · strength 0.54
  8. Davide Melisi · 3 shared papers, 2023–2025 · strength 0.54
  9. Tanios Bekaii‐Saab · 3 shared papers, 2023–2025 · strength 0.54
  10. Richard A Hubner · 3 shared papers, 2023–2025 · strength 0.54
  11. Shubham Pant · 3 shared papers, 2023–2025 · strength 0.54
  12. Eric Van Cutsem · 3 shared papers, 2023–2025 · strength 0.54
  13. Teresa Mercade Macarulla · 3 shared papers, 2023–2025 · strength 0.54
  14. Ondřej Slabý · 5 shared papers, 2015–2020 · strength 0.45
  15. Zdeněk Kala · 5 shared papers, 2015–2020 · strength 0.45
  16. Natalia Gabło · 4 shared papers, 2018–2020 · strength 0.41
  17. Vladimír Procházka · 4 shared papers, 2015–2020 · strength 0.35
  18. Andrew Peter Dean · 2 shared papers, 2023–2025 · strength 0.34
  19. Jan Hlavsa · 4 shared papers, 2015–2020 · strength 0.33
  20. Woo Jin Lee · 1 shared paper, 2023 · strength 0.14
  21. Markéta Hermanová · 2 shared papers, 2015–2018 · strength 0.12
  22. Petra Vychytilova‐Faltejskova · 2 shared papers, 2015–2018 · strength 0.12
  23. Petr Karásek · 2 shared papers, 2015–2018 · strength 0.12
  24. Martin Loveček · 1 shared paper, 2020 · strength 0.10
  25. Ioana Berindan‐Neagoe · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.